Skip to main navigation
Skip to search
Skip to main content
Sort by
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Neoplasm
71%
Pharmacokinetic
29%
Polyethylene Terephthalate
28%
Immunotherapy
23%
Immune Checkpoint Inhibitor
22%
Fluorine 18
19%
Erlotinib
19%
Zirconium 89
18%
Carbon 11
16%
Overall Survival
16%
Protein Tyrosine Kinase Inhibitor
16%
Pembrolizumab
15%
Biological Marker
15%
Osimertinib
14%
Medicine and Dentistry
Non Small Cell Lung Cancer
84%
Neoplasm
35%
Polyethylene Terephthalate
25%
Lung Cancer
24%
Durvalumab
24%
Immunotherapy
22%
Immune Checkpoint Inhibitor
18%
Non-Small Cell Lung Cancer
16%
Zirconium 89
15%
Overall Survival
15%
Lung Tumor
14%
Fluorine-18
14%
Lung Adenocarcinoma
14%
Positron Emission Tomography-Computed Tomography
14%
Tumor Microenvironment
12%
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
40%
Positron Emission Tomography
24%
Tumor
19%
Zirconium-89 (89Zr)
18%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
16%
Programmed Death-ligand 1 (PD-L1)
15%
Durvalumab
14%
Overall Survival
13%
Tumor Response
10%
Non-small Cell Lung Cancer Patients
10%
Progression-free Survival
9%
89Zr-immuno-PET
9%
Whole-body
9%
Stage III Non-small Cell Lung Cancer
9%
Cell-free DNA (cfDNA)
9%